All In Biotech

Drug Trial Radar · NCT06097273

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,061 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,061

Actual

Start

Oct 19, 2023

Primary completion

May 28, 2024

Study completion May 28, 2024

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Oct 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).

Conditions

  • SARS-CoV-2
  • Influenza

Interventions

  • mRNA-1083Biological

    Suspension for injection

  • PlaceboBiological

    0.9% sodium chloride suspension for injection

  • Influenza VaccineBiological

    Commercially available formulation (Suspension for injection \[pre-filled syringe\])

  • COVID-19 VaccineBiological

    Commercially available formulation (Suspension for injection)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean (GM) Level of Antibodies for Influenza, as Measured by Hemagglutination Inhibition (HAI) AssayTime frame: Day 29
  2. GM Level of Antibodies for SARS-CoV-2, as Measured by Pseudovirus Neutralization Assay (PsVNA)Time frame: Day 29
  3. Influenza: Percentage of Participants With Seroconversion, as Measured by HAI AssayTime frame: Baseline to Day 29
  4. SARS-CoV-2: Percentage of Participants With Seroresponse, as Measured by PsVNATime frame: Baseline to Day 29
  5. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to 7 days after study injection
  6. Number of Participants With Unsolicited Adverse Events (AEs)Time frame: Up to 28 days after study injection
  7. Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to DiscontinuationTime frame: Day 1 through Day 181

Locations

146 sites in 1 country. Site status is shown where the registry gives one.

  • Pinnacle Research Group-409 E 10th St

    Anniston, Alabama

  • Accel Research Site - Achieve - Birmingham

    Birmingham, Alabama

  • Cullman Clinical Trials

    Cullman, Alabama

  • Desert Clinical Research - CCT - PPDS

    Mesa, Arizona

  • Foothills Research Center - CCT - PPDS

    Phoenix, Arizona

  • Headlands Research - Scottsdale - PPDS

    Scottsdale, Arizona

  • Scottsdale Clinical Trials

    Scottsdale, Arizona

  • Fiel Family & Sports Medicine - PC - CCT - PPDS

    Tempe, Arizona

  • AES - DRS - Synexus Clinical Research US, Inc. - Cerritos

    Cerritos, California

  • Long Beach Research Institute, LLC

    Long Beach, California

  • CenExel Apex (CNS) - Los Alamitos - PPDS

    Los Alamitos, California

  • Central Valley Research, LLC

    Modesto, California

  • Carbon Health- NoHo West Urgent Care and Primary Care

    North Hollywood, California

  • Empire Clinical Research

    Pomona, California

  • Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS

    Riverside, California

  • Clinical Innovations Trials - Riverside - CenExel - PPDS

    Riverside, California

  • Peninsula Research Associates - Headlands - PPDS

    Rolling Hills Estates, California

  • Artemis Institute For Clinical Research LLC - San Diego - Headlands - PPDS

    San Diego, California

  • AES - DRS - Synexus Clinical Research US, Inc. - Vista

    Vista, California

  • Tekton Research - Fort Collins - PPDS

    Fort Collins, Colorado

  • Tekton Research - Longmont - PPDS

    Longmont, Colorado

  • Stamford Therapeutics Consortium - ERN - PPDS

    Stamford, Connecticut

  • Chase Medical Research LLC - Waterbury

    Waterbury, Connecticut

  • Revival Research Corporation

    Doral, Florida

  • Indago Research and Health Center

    Hialeah, Florida

  • CenExel RCA - Hollywood

    Hollywood, Florida

  • Nature Coast Clinical Research

    Inverness, Florida

  • Jacksonville Center For Clinical Research

    Jacksonville, Florida

  • Health Awareness - Jupiter - ERN - ERN

    Jupiter, Florida

  • Accel Research Sites - Saint Petersburg - Largo - ERN - PPDS

    Largo, Florida

  • Flourish Research - Leesburg - PPDS

    Leesburg, Florida

  • Accel Research Sites - Maitland

    Maitland, Florida

  • AES - DRS - Optimal Research Florida - Melbourne

    Melbourne, Florida

  • Suncoast Research Group LLC - Flourish - PPDS

    Miami, Florida

  • St. Johns Center for Clinical Research - ERN - PPDS

    Saint Augustine, Florida

  • ForCare Clinical Research - CenExel FCR - PPDS

    Tampa, Florida

  • AES - DRS - Synexus Clinical Research US, Inc. - Atlanta

    Atlanta, Georgia

  • DelRicht Research, LLC - Springer Wellness & Restorative - Atlanta - PPDS

    Atlanta, Georgia

  • iResearch Atlanta - CenExel - PPDS

    Decatur, Georgia

  • Javara, Inc./Privia Medical Group Georgia, LLC - Fayetteville - Javara - PPDS

    Fayetteville, Georgia

Showing 40 of 146 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.